BCIQ Profiles

Company Profile Report
0805 ECP PepGen
BioCentury & Getty Images

Emerging Company Profile 

PepGen: $112.5M round for cell-penetrating oligos and a Boston build-out

Emerging Company Profile: PepGen’s crossover round to take at least two muscular dystrophy assets into the clinic

PepGen’s crossover round will help the company to take at least two muscular dystrophy programs into the clinic and build out its new headquarters in Boston.

Aug 6, 2021 | 12:53 AM GMT

With a fresh $112.5 million in crossover funding, PepGen is prepared to take at least two muscular dystrophy therapies into

Read the full 858 word article

How to gain access

Continue reading with a
two-week free trial.